Glycine Magnesium: Recent Market Dynamics and Analysis Forecast

I. Market Price Dynamics
1. Domestic Quotations
- Suzhou City, Jiangsu Province: As of April 30, 2026, Jiangsu XinSu’s ex-factory price for 20% glycine magnesium was RMB 30,000 per metric ton.
- Chengdu City, Sichuan Province: As of May 7, 2026, spot quotations for food-grade glycine magnesium stood at RMB 40 per kilogram and above (for orders ≥1 kg), with total available supply reaching 800 million kilograms; multiple suppliers quoted within the range of RMB 40–64 per kilogram.
- Shijiazhuang City, Hebei Province: As of May 8, 2026, Shijiazhuang Donghua Jinlong Chemical quoted RMB 50,000 per metric ton for 2,000 tons of food additive-grade glycine magnesium.

2. Price Volatility Characteristics
- Industrial-grade products (purity 98.5%) averaged RMB 68.5 per kilogram in 2025, down 2.1% year-on-year, driven by cost reductions from scaled-up production and lower raw material prices.
- Pharmaceutical-grade products (purity ≥99.5%) maintained an average price of RMB 126.8 per kilogram, up 0.7% year-on-year, reflecting structural premium pricing in high-end supply segments.

II. Supply-Demand Analysis
1. Supply Side
- Production Capacity Distribution: The East China region remains the core production base, accounting for 54.3% of national output in 2025—Zhejiang (23.1%), Jiangsu (18.7%), and Shandong (12.5%). Central and Western regions demonstrated significant growth, with a 18.4% year-on-year increase in 2025.
- Enterprise Landscape:
- Major industrial-grade suppliers include Shandong Jinyang Biotech (3,200-ton annual GMP-certified capacity), Zhejiang NHU (2,800 tons), and Jiangsu EnHua Pharma (1,900 tons), collectively representing 67.3% of market share.
- Jiangsu Caiwei has commissioned China’s first intelligent production line for pharmaceutical-grade glycine magnesium (99.95% purity), with an annual capacity of 1,200 tons. Shaanxi Chenming and Hebei Hongtao completed technological upgrades to their food-grade lines (99.9% purity), adding 2,100 tons of new capacity.
- Import Dependence: In 2025, Sumitomo Chemical (Japan) and Merck (Germany) jointly exported 4,860 tons of pharmaceutical-grade glycine magnesium to China, representing 71.5% of domestic supply. Their landed price was RMB 286,000 per ton—64.2% higher than the domestic average.

2. Demand Side
- Consumption Scale: Terminal consumption reached 32,000 metric tons in 2025, accounting for 42.7% of total magnesium supplement consumption—a 7.6 percentage-point increase year-on-year.
- Application Scenarios:
- Premium Multivitamin Gummies: Bytedance (Tangchen Beijian) procured 386 tons in 2025, up 29.4% year-on-year.
- OTC Sleep-Aid Compound Formulations: China Resources Sanjiu’s An Shen Ning Pian tablets sourced 192 tons, with an average procurement price of RMB 186.5 per kilogram—up 11.3% year-on-year.
- Infant Formula Milk Powder: Feihe and Junlebao’s third-generation premium series collectively consumed 217 tons, representing 34.2% of total food-grade usage.
- Sports Nutrition Segment: Penetration rate surged from 12.4% in 2024 to an estimated 29.7% in 2026, driving demand for protein powders and electrolyte beverages.

III. Industry Drivers
1. Policy Tailwinds
- The National Health Commission has incorporated magnesium intake compliance rates into the evaluation metrics of the Healthy China Initiative, accelerating functional food innovation and upgrading.
- Implementation of the “National Food Safety Standard—Food Nutrient Fortifier: Glycine Magnesium” (GB 1903.42–2025) establishes mandatory minimum magnesium content (≥9.5%), maximum chloride residue (≤0.15%), and microbiological specifications—spurring quality standard upgrades across the industry.

2. Technological Breakthroughs
- The Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, developed an enzymatic synthesis pathway achieving 99.2% yield and ultra-low heavy metal residues (Pb/As < 0.1 ppm). This technology is being commercialized by Zhejiang NHU, with mass production scheduled for Q3 2026—expected to narrow the import premium on high-end products by up to 34%.

IV. Market Forecast and Risks
1. Short-Term Outlook (2026)
- Market Size: Expected to reach RMB 650 million, growing 12.1% year-on-year; pharmaceutical-grade applications projected to grow at 18.3%, surpassing food-grade growth (10.6%) for the first time.
- Price Trend: Pharmaceutical-grade prices will see moderated growth due to accelerating import substitution; industrial-grade prices face downward pressure amid increased capacity release.

2. Long-Term Risks
- Overcapacity Risk: Unchecked expansion by new entrants may trigger diminishing marginal returns.
- Regulatory Uncertainty: Should the National Medical Products Administration (NMPA) list glycine magnesium in the “Catalogue of Existing Cosmetic Ingredients,” the cosmetics segment could unlock an incremental RMB 80 million market opportunity.

V. Investment Recommendations
1. Priority Investment Targets
- Companies equipped with continuous crystallization and purification lines (raising pharmaceutical-grade first-pass yield to 92.5%) and downstream formulation development capabilities—e.g., Shandong Jinyang Biotech (79.4% of 2026 orders already secured).
- Enterprises holding EU COS certification or having passed U.S. FDA on-site inspections—e.g., Zhejiang Medicine and Northeast Pharmaceutical.

2. Risk Mitigation
- Avoid investments in projects lacking high-precision metal ion separation systems (e.g., integrated nanofiltration + chelating resin systems) or those without long-term supply agreements.